These insights suggest that targeting the sclerostin–Wnt signaling pathway could represent a promising therapeutic approach for managing IJO and other pediatric bone disorders characterized by reduced bone formation. The gene discussed is SOST; the disease is idiopathic juvenile osteoporosis.